[{"id":"44c07294-8489-4b3a-b2ed-b2c7e11ad982","acronym":"NCI#10057","url":"https://clinicaltrials.gov/study/NCT02978625","created_at":"2021-01-18T14:39:10.615Z","updated_at":"2025-02-25T13:48:20.165Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","source_id_and_acronym":"NCT02978625 - NCI#10057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • ALK • NECTIN1","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["PD-L1 • ALK • NECTIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Imlygic (talimogene laherparepvec) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-21"},{"id":"39be432b-e1d2-4ded-8099-18c4960548fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06805825","created_at":"2025-02-25T15:15:39.171Z","updated_at":"2025-02-25T15:15:39.171Z","phase":"Phase 1","brief_title":"A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit","source_id_and_acronym":"NCT06805825","lead_sponsor":"Novelty Nobility, Inc.","biomarkers":" KIT","pipe":"","alterations":" ","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NN3201"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 02/03/2025","start_date":" 02/03/2025","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-13"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"f93bea8a-4ae1-4cd6-ae81-5b0519b817f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06521775","created_at":"2025-02-27T07:54:44.561Z","updated_at":"2025-02-27T07:54:44.561Z","phase":"Phase 2","brief_title":"An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients with Metastatic Adenoid Cystic Carcinoma","source_id_and_acronym":"NCT06521775","lead_sponsor":"Mayo Clinic","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 5","initiation":"Initiation: 08/12/2024","start_date":" 08/12/2024","primary_txt":" Primary completion: 08/12/2025","primary_completion_date":" 08/12/2025","study_txt":" Completion: 08/12/2025","study_completion_date":" 08/12/2025","last_update_posted":"2024-09-23"},{"id":"15ebc24f-836d-4955-b1c1-9b9491f8cda7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04895735","created_at":"2021-05-20T11:54:07.989Z","updated_at":"2024-07-02T16:34:26.348Z","phase":"Phase 2","brief_title":"Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer","source_id_and_acronym":"NCT04895735","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1 • MTAP • TYMS","pipe":" | ","alterations":" PD-L1 expression • TYMS expression","tags":["PD-L1 • MTAP • TYMS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • TYMS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 07/23/2021","start_date":" 07/23/2021","primary_txt":" Primary completion: 06/03/2025","primary_completion_date":" 06/03/2025","study_txt":" Completion: 06/03/2026","study_completion_date":" 06/03/2026","last_update_posted":"2024-06-13"},{"id":"a3d44513-3d22-4617-a3e3-b78c69f0ade8","acronym":"SGNB7H4V-001","url":"https://clinicaltrials.gov/study/NCT05194072","created_at":"2022-01-18T12:54:03.783Z","updated_at":"2024-07-02T16:34:27.305Z","phase":"Phase 1","brief_title":"A Study of SGN-B7H4V in Advanced Solid Tumors","source_id_and_acronym":"NCT05194072 - SGNB7H4V-001","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e felmetatug vedotin (PF-08046048)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 01/12/2022","start_date":" 01/12/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-06-11"},{"id":"c992b4e8-e799-41ef-b989-1921ae3a3287","acronym":"","url":"https://clinicaltrials.gov/study/NCT03556228","created_at":"2021-01-18T17:30:17.557Z","updated_at":"2024-07-02T16:34:59.667Z","phase":"Phase 1","brief_title":"Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","source_id_and_acronym":"NCT03556228","lead_sponsor":"VM Oncology, LLC","biomarkers":" NTRK1","pipe":" | ","alterations":" NTRK1 fusion • NTRK1 mutation • NTRK expression","tags":["NTRK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK1 mutation • NTRK expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VMD-928"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 06/08/2018","start_date":" 06/08/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-31"},{"id":"78300dda-68e6-4423-8fb4-e493ba460a0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04832438","created_at":"2021-04-05T12:53:00.094Z","updated_at":"2024-07-02T16:36:16.800Z","phase":"Phase 2","brief_title":"9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma","source_id_and_acronym":"NCT04832438","lead_sponsor":"Actuate Therapeutics Inc.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • elraglusib (9-ING-41)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/18/2030","start_date":" 12/18/2030","primary_txt":" Primary completion: 06/18/2033","primary_completion_date":" 06/18/2033","study_txt":" Completion: 06/18/2034","study_completion_date":" 06/18/2034","last_update_posted":"2022-02-22"},{"id":"97d359bc-0674-4d9f-a5d6-11b5987b3936","acronym":"","url":"https://clinicaltrials.gov/study/NCT00859937","created_at":"2021-01-18T03:16:42.805Z","updated_at":"2024-07-02T16:37:11.327Z","phase":"Phase 2","brief_title":"Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors","source_id_and_acronym":"NCT00859937","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression • KIT overexpression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression • KIT overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 03/16/2009","start_date":" 03/16/2009","primary_txt":" Primary completion: 01/30/2013","primary_completion_date":" 01/30/2013","study_txt":"","study_completion_date":"","last_update_posted":"2018-04-20"},{"id":"1914a323-8d0c-459e-bc03-802d30972fbc","acronym":"","url":"https://clinicaltrials.gov/study/NCT00095563","created_at":"2021-01-18T00:17:39.239Z","updated_at":"2024-07-02T16:37:23.300Z","phase":"Phase 2","brief_title":"Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers","source_id_and_acronym":"NCT00095563","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" HER-2 expression • EGFR expression","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 09/01/2004","start_date":" 09/01/2004","primary_txt":" Primary completion: 02/01/2009","primary_completion_date":" 02/01/2009","study_txt":" Completion: 06/01/2009","study_completion_date":" 06/01/2009","last_update_posted":"2017-04-18"}]